The upcoming expiry of the semaglutide patent in India in mid-March 2026 is expected to transform the country's diabetes treatment landscape. Ahead of this, industry experts predict that the ...

Novo Nordisk AS has slashed prices of its blockbuster weight-loss drugs Ozempic and Wegovy in India, amid an onslaught of copycat drugs in the world's third most overweight population. Many patients ...

Strides Pharma International AG (SPIAG), a step-down subsidiary of Strides Pharma Science Limited, has signed an agreement for the acquisition and in-licensing of a portfolio of branded generic ...

AI Quick Read MUMBAI: A day after semaglutide lost patent protection in India, top drugmakers including Dr Reddy’s, Sun Pharma, and Zydus Lifesciences launched generic versions priced 50-90% below the ...

Danish pharmaceutical giant Novo Nordisk on Tuesday announced price cuts of up to 48% on its blockbuster diabetes and obesity drugs Ozempic and Wegovy in India, weeks after semaglutide—the active ...

India’s weight-loss drug market is on the verge of a price shake-up. In days, domestic drugmakers are set to launch cheaper versions of semaglutide, the GLP-1 (glucagon-like peptide-1) therapy popular ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with content, and download exclusive resources. Agent workflows make transport a first-order ...

Novo lost semaglutide patent protection in India, triggering generic launches. Indian drugmakers launched generic versions at lower prices. Novo cut prices and used partnerships to defend market share ...

A massive shake-up is underway in India's obesity and diabetes drug market as the patent for Semaglutide—the key ingredient behind blockbuster drugs—expires. This opens the floodgates for over 40 ...